Banke Agarwal1, Arlene M Correa, Linus Ho. 1. Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA. agarwalb@slu.edu
Abstract
OBJECTIVES: The size of pancreatic tumors that can be diagnosed by preoperative imaging continues to decrease because advances in diagnostic imaging. Several surgical series have suggested that survival is better in tumors 20 mm or smaller (vs tumors >20 mm), but the incremental benefit of diagnosing progressively smaller tumors from 30 mm (currently, the average size of pancreatic tumor at diagnosis) to 20 mm or smaller is not known. We investigated survival and resectability as tumor size increased from 20 mm or smaller to 30 mm or larger. METHODS: This is a retrospective analysis of consecutive patients with pancreatic cancer, who underwent endoscopic ultrasound-guided fine-needle aspiration at MD Anderson Cancer Center between December 2000 and December 2001. Tumor size was based on the combination of endoscopic ultrasound and computed tomography imaging. RESULTS: The median (+/-SE) for tumors 20 mm or smaller, 21 to 25 mm, 26 to 30 mm and larger than 30 mm was 17.2 +/- 8.2, 12.3 +/- 4.9, 8.5 +/- 3.6, and 7.6 +/- 1.2 months (P = 0.021), respectively. Tumors were resectable in 10 (83%) of 12 tumors 20 mm or smaller, 8 (67%) of 12 tumors 21 to 25 mm, 5 (36%) of 14 of tumors 26 to 30 mm, and 2 (7%) of 27 tumors larger than 30 mm (P < 0.001). CONCLUSIONS: A dramatic change in survival occurs as the size of pancreatic tumor increases from 20 mm or smaller to 30 mm or larger. To be effective, future strategies for early diagnosis of pancreatic cancer should aim at diagnosing most pancreatic cancers before they are 20 mm in size.
OBJECTIVES: The size of pancreatic tumors that can be diagnosed by preoperative imaging continues to decrease because advances in diagnostic imaging. Several surgical series have suggested that survival is better in tumors 20 mm or smaller (vs tumors >20 mm), but the incremental benefit of diagnosing progressively smaller tumors from 30 mm (currently, the average size of pancreatic tumor at diagnosis) to 20 mm or smaller is not known. We investigated survival and resectability as tumor size increased from 20 mm or smaller to 30 mm or larger. METHODS: This is a retrospective analysis of consecutive patients with pancreatic cancer, who underwent endoscopic ultrasound-guided fine-needle aspiration at MD Anderson Cancer Center between December 2000 and December 2001. Tumor size was based on the combination of endoscopic ultrasound and computed tomography imaging. RESULTS: The median (+/-SE) for tumors 20 mm or smaller, 21 to 25 mm, 26 to 30 mm and larger than 30 mm was 17.2 +/- 8.2, 12.3 +/- 4.9, 8.5 +/- 3.6, and 7.6 +/- 1.2 months (P = 0.021), respectively. Tumors were resectable in 10 (83%) of 12 tumors 20 mm or smaller, 8 (67%) of 12 tumors 21 to 25 mm, 5 (36%) of 14 of tumors 26 to 30 mm, and 2 (7%) of 27 tumors larger than 30 mm (P < 0.001). CONCLUSIONS: A dramatic change in survival occurs as the size of pancreatic tumor increases from 20 mm or smaller to 30 mm or larger. To be effective, future strategies for early diagnosis of pancreatic cancer should aim at diagnosing most pancreatic cancers before they are 20 mm in size.
Authors: Andrew D Rhim; Fredrik I Thege; Steven M Santana; Timothy B Lannin; Trisha N Saha; Shannon Tsai; Lara R Maggs; Michael L Kochman; Gregory G Ginsberg; John G Lieb; Vinay Chandrasekhara; Jeffrey A Drebin; Nuzhat Ahmad; Yu-Xiao Yang; Brian J Kirby; Ben Z Stanger Journal: Gastroenterology Date: 2013-12-13 Impact factor: 22.682
Authors: Stefan Eser; Marlena Messer; Philipp Eser; Alexander von Werder; Barbara Seidler; Monther Bajbouj; Roger Vogelmann; Alexander Meining; Johannes von Burstin; Hana Algül; Philipp Pagel; Angelika E Schnieke; Irene Esposito; Roland M Schmid; Günter Schneider; Dieter Saur Journal: Proc Natl Acad Sci U S A Date: 2011-05-31 Impact factor: 11.205
Authors: Nils D Arvold; Andrzej Niemierko; Harvey J Mamon; Carlos Fernandez-del Castillo; Theodore S Hong Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-12 Impact factor: 7.038
Authors: Kazufumi Honda; Verena A Katzke; Anika Hüsing; Shinobu Okaya; Hirokazu Shoji; Kaoru Onidani; Anja Olsen; Anne Tjønneland; Kim Overvad; Elisabete Weiderpass; Paolo Vineis; David Muller; Kostas Tsilidis; Domenico Palli; Valeria Pala; Rosario Tumino; Alessio Naccarati; Salvatore Panico; Krasimira Aleksandrova; Heiner Boeing; H Bas Bueno-de-Mesquita; Petra H Peeters; Antonia Trichopoulou; Pagona Lagiou; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Susana Merino; Eric J Duell; Miguel Rodríguez-Barranco; María Dolores Chirlaque; Aurelio Barricarte; Vinciane Rebours; Marie-Chiristine Boutron-Ruault; Francesca Romana Mancini; Paul Brennan; Ghislaine Scelo; Jonas Manjer; Malin Sund; Daniel Öhlund; Federico Canzian; Rudolf Kaaks Journal: Int J Cancer Date: 2018-12-04 Impact factor: 7.396
Authors: Willemieke S Tummers; Juergen K Willmann; Bert A Bonsing; Alexander L Vahrmeijer; Sanjiv S Gambhir; Rutger-Jan Swijnenburg Journal: Pancreas Date: 2018-07 Impact factor: 3.327